Tissue scaffolds

ABSTRACT

Tissue scaffolds are described herein. Also described are devices for treating wounds and methods of treating wounds using tissue scaffolds.

This application is a continuation of U.S. patent application Ser. No.12/540,489, filed Aug. 13, 2009, which claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application No. 61/189,097, which wasfiled on Aug. 14, 2008, both of which are herein incorporated byreference.

BACKGROUND

Reduced pressure, or vacuum-assisted, therapies can be effective forimproving wound healing due to a variety of different causes and at anumber of different anatomical locations. Typically, reduced pressuretherapies include a porous material that is placed at a wound site,which aids in the distribution of the reduced pressure. Typical porousmaterials are sized to fit the wound, and may be periodically replacedwith smaller pieces of the porous material as the wound begins to healand becomes smaller. Typically, a membrane or drape is placed over theporous material to provide an airtight seal at the wound area, and anegative pressure is applied to the porous material to provide a reducedpressure at the wound site.

SUMMARY

According to certain embodiments, a method of processing an acellulartissue matrix for preparing a tissue scaffold is provided. In certainembodiments, a method of preparing a tissue scaffold is provided,comprising adding an acellular tissue matrix to a first aqueous solutionof sodium acetate; incubating the first aqueous sodium acetate solutioncontaining the acellular tissue matrix; removing the incubated acellulartissue matrix from the first aqueous sodium acetate solution; treatingthe incubated acellular tissue matrix with a second aqueous solution ofsodium acetate to form a suspension; homogenizing the suspension to forma slurry; cooling the slurry; casting the slurry in a casting container;and lyophilizing the slurry. In certain embodiments, a tissue scaffoldcomprising an acellular tissue matrix and sodium acetate is provided. Incertain embodiments, a wound treatment device comprising a reducedpressure source and a tissue scaffold is provided. In certainembodiments, a tissue scaffold, comprising an acellular tissue matrixthat has been processed to have a porosity of between 75% and 90% isprovided.

DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a wound treatment device, which provides reducedpressure therapy, according to certain exemplary embodiments.

FIG. 2 illustrates a method of treating a cartilage defect using atissue scaffold, according to certain embodiments.

FIGS. 3A-3D are graphs showing the strut spacing for tissue scaffolds,as described in Example 1.

FIG. 4 is a graph showing the permeability versus composition for tissuescaffolds, as described in Example 2.

FIG. 5 is a graph showing the strut spacing for a tissue scaffoldproduced according to certain exemplary embodiments, as described inExample 3.

FIGS. 6A-6B are photomicrographs of chondrocytes cultured on tissuescaffolds, as described in Example 4.

FIGS. 7A-7B are photomicrographs of chondrocytes cultured on tissuescaffolds, as described in Example 4

DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS

Reference will now be made in detail to the certain exemplaryembodiments according to the present disclosure, certain examples ofwhich are illustrated in the accompanying drawing.

The present disclosure pertains to a method of processing an acelluartissue matrix for preparing a tissue scaffold. In some embodiments, thetissue scaffold of the present disclosure may be used as part of a woundtreatment device that provides reduced pressure therapy. In someembodiments, the physical properties of certain tissue scaffolds such asporosity, strut density, and permeability, may be controlled or alteredby adjusting the concentrations, components, and temperatures at whichthe scaffolds are produced.

In this application, the use of the singular includes the plural unlessspecifically stated otherwise. In this application, the use of “or”means “and/or” unless stated otherwise. Furthermore, the use of the term“including”, as well as other forms, such as “includes” and “included”,is not limiting. Also, terms such as “element” or “component” encompassboth elements and components comprising one unit and elements andcomponents that comprise more than one subunit, unless specificallystated otherwise. Also the use of the term “portion” may include part ofa moiety or the entire moiety.

The term “acellular tissue matrix,” as used herein, refers generally toany tissue matrix that is substantially free of cells and otherantigenic material. In various embodiments, acellular tissue matricesderived from human or xenogenic sources may be used to produce thescaffolds. Skin, parts of skin (e.g., dermis), and other tissues such asblood vessels, heart valves, fascia, nerve, or other collagencontaining-organ or tissue may be used to create an acellular matricesto produce tissues scaffolds within the scope of the present disclosure.

In certain embodiments, the term “permeability” refers generally to themovement of fluid through a porous medium. In certain embodiments, thespecific permeability values of particular tissue scaffolds arecalculated by Darcy's Law:

$k = \frac{Q \cdot I \cdot \mu}{\Delta \; {P \cdot A}}$

where Q equals the total discharge (units of volume per time, e.g.,m²/s), (A) is the cross-sectional area to flow, AP is the pressure dropacross the system, p is the dynamic viscosity (in SI units e.g. kg/(m s)or Pa's), and (l) is the length over which the pressure drop is takingplace over.

The term “reduced pressure,” as used herein, generally refers to apressure less than the ambient pressure at a tissue site that is beingsubjected to treatment. In most cases, this reduced pressure will beless than the atmospheric pressure at which the patient is located.Alternatively, the reduced pressure may be less than a hydrostaticpressure of tissue at the tissue site. Reduced pressure may initiallygenerate fluid flow in the area of the tissue site and/or a fluidconduit in communication with the tissue site, for example, as shown inFIG. 1. As the hydrostatic pressure around the tissue site approachesthe desired reduced pressure, the flow may subside, and the reducedpressure is then maintained. In some embodiments, small amounts of gascan be introduced at intervals to facilitate fluid movement if required.Unless otherwise indicated, values of pressure stated herein are gagepressures.

The term “fluid” as used herein generally refers to a gas or liquid, butmay also include any other flowable material, including but not limitedto gels, colloids, and foams.

The section headings used herein are for organizational purposes onlyand are not to be construed as limiting the subject matter described.All documents, or portions of documents, cited in this application,including but not limited to patents, patent applications, articles,books, and treatises, are hereby expressly incorporated by reference intheir entirety for any purpose.

In various embodiments, devices of the present disclosure can be usedfor treatment at numerous different anatomical sites. According tovarious embodiments, tissue scaffolds can be used in a wide array ofapplications. Certain exemplary applications include, but are notlimited to, absorptive dressing, dermal regeneration (for example, fortreatments of all types of ulcers and burns), nerve regeneration,cartilage regeneration, connective tissue regeneration or repair (forexample, tendon/ligament sleeve), bone regeneration, periodontalapplications, wound/foam lining, integrated bandage dressing,substrate/base for skin grafts, vascular regeneration, cosmetic surgery,cosmetic injectable gel, metal and/or polymer implant coating (forexample, to increase implant integration and biocompatibility), andreplacement of lost tissue (e.g., after trauma, breast reduction,mastectomy, lumpectomy, parotidectomy, or excision of tumors).

FIG. 1 illustrates a wound treatment device 100, including a reducedpressure source 120, according to certain exemplary embodiments. Invarious embodiments, a variety of reduced pressure therapy devices canbe used. For example, suitable reduced pressure therapy devices includeV.A.C.® therapy devices produced by Kinetic Concepts, Inc. (San Antonio,Tex.). Such reduced pressure therapy devices can include a vacuum pumpthat can be fluidly connected to the wound site 150, via a fluid conduit125 or other fluid connection. Such devices may also include a flexiblesheet 160 to cover the wound site 150 and at least partially seal thewound to allow reduced pressure therapy to be provided at the woundsite. In addition, such systems may include a tissue scaffold 180, thatis placed at the wound site and facilitates wound closure, healing,tissue regeneration or repair, prevents or treats infection, and/or hasother beneficial effects. In certain embodiments, the tissue scaffold180 assists in distributing fluid flow or negative pressure across asite to be treated.

In some embodiments, the flexible sheet 160 will include a flexiblepolymeric material. In various embodiments, any suitable polymericmaterial can be selected. In various embodiments, the material does notcause significant irritation, immune response, or heightened risk ofinfection. In various embodiments, the specific material generallyshould be of sufficient thickness and impermeability to allow reducedpressure therapy at a wound site under the sheet 160.

In some embodiments, the device 100 will include an adhesive. As usedhere, and throughout the disclosure, adhesive will be understood torefer to any substance that causes the surfaces of two objects to beattached to one another. In various embodiments, suitable adhesives caninclude a variety of different cements, glues, resins, or othermaterials that can facilitate attachment of the flexible sheet 160 totissue. In some embodiments, the adhesive can include apressure-sensitive acrylic adhesive. In various embodiments, theadhesives can be applied directly to the structures to be joined, or theadhesives may be applied on tape, or with other supporting substratematerials.

In some embodiments, the adhesive can be applied to a surface of theflexible sheet 160 to attach the sheet to skin or other tissue. In someembodiments, the adhesive will be applied to the surface of the sheetand packaged and/or distributed with the sheet 160. In some embodiments,the adhesive is applied to a surface of the sheet 160 and covered by anon-adhesive material that can be removed to expose the adhesive foruse. In certain embodiments, the adhesive can be supplied as a separatecomponent (e.g., in a container or on a tape) that is applied to thesheet 160 to attach the sheet 160 to tissue. In some embodiments, theadhesive can be applied to a patient's skin or other tissue, and thesheet can be applied to the adhesive.

In various embodiments, tissue scaffold 180 can include a variety ofsuitable materials. For example, a number of different tissue scaffoldswill be compatible for use with the above-noted V.A.C.® treatmentsystems. In some embodiments, the tissue scaffold may comprise aprocessed acellular tissue matrix. In some embodiments, the acellulartissue matrix may be derived from human skin or from a xenogenic source.In various embodiments, other tissues such as blood vessels, heartvalves, fascia, nerve, connective tissue, or other collagen-containingorgans or tissues may be used to create a specific acellular matrixwithin the scope of the present disclosure. In some embodiments, theacellular tissue matrix is an acellular dermal matrix. In variousembodiments, the acellular dermal matrix is produced from human dermisor pig dermis. In some embodiments, the methods disclosed herein utilizea dehydrated acellular tissue matrix tissue, such as ALLODERM®, which iscommercially available from LifeCell Corporation, Branchburg, N.J. Insome embodiments, the methods disclosed herein utilize an acellulartissue matrix tissue, such as STRATTICE™, which is commerciallyavailable from LifeCell Corporation, Branchburg, N.J.

In various embodiments, acellular tissue matrices can be produced usinga variety of different tissue processing techniques. For example,certain exemplary tissue processing techniques for producing acellulartissue matrices are described in U.S. Pat. Nos. 5,336,616 and 5,364,756,both to Livesey et al., in U.S. Pat. No. 6,933,326 to Schiff et al.,each of which is incorporated by reference in its entirety. In someembodiments, acellular tissue matrices made from non-human animals canbe treated to remove various antigens, or produced from animalsgenetically modified to lack certain antigens. For example, certainexemplary methods of processing tissues to produce acellular matriceswith reduced amounts of or lacking alpha-1,3-galactose moieties, aredescribed in Hui, X. et al., “A Porcine-Derived Acellular DermalScaffold that Supports Soft Tissue Regeneration: Removal of TerminalGalactose-a-(1,3)-Galactose and Retention of Matrix Structure,” TissueEngineering, Vol. 15, 1-13 (2009), which is incorporated by reference inits entirety

FIG. 2 illustrates use of a tissue scaffold to treat a cartilage defect,according to certain embodiments. As shown, a scaffold 180 is used totreat a cartilage defect in a long bone (e.g., femur or humerus). Invarious embodiments, a scaffold 180 can be used to treat an articularsurface or cartilage 510 of any joint. In various embodiments, thetissue scaffold 180 is placed in a defect or excised area of anarticular surface or cartilage 510, and a negative pressure is appliedto the tissue scaffold 180 through a fluid conduit 125, as describedabove. In some embodiments, a second material 190 is applied over thetissue scaffold 180, and the second material 190 acts as a manifold todistribute pressure to tissue scaffold 180. In some embodiments, thefluid conduit is in fluid communication with the tissue scaffold 180without a second material 180.

In some embodiments, the tissue scaffold can be used as a primarytreatment method or in connection with another procedure or treatment.For example, in various embodiments, cartilage repair or regenerationcan be performed using a technique known in the art as microfracture. Asshown in FIG. 2, during a microfracture procedure, a surgeon createssmall fractures or openings 515 in bone adjacent to an articular defect.In various instances, the fractures or openings 515 can allowchondrocytes or other cells that can differentiate into chondrocytes tomigrate to the articular defect from adjacent bone, bone marrow space,or cartilage. In various instances, these cells can, in turn, helprepair or regenerate cartilage.

In some embodiments, after the fractures or openings 515 are produced inthe bone 500, the tissue scaffold 180 is placed over the microfracturesite, and negative pressure is applied to the scaffold. In someembodiments, the tissue scaffold acts as a manifold to distributenegative pressure over the site to be treated. In some embodiments, thetissue scaffold provides a substrate to support tissue growth, repair,and/or regeneration. In some embodiments, negative pressure is appliedto draw cells, growth factors, and/or other biologic elements into thetissue scaffold 180 from the bone 500.

In some embodiments, a method of processing an acellular tissue matrixto produce a tissue scaffold is provided. In some embodiments, theacellular tissue matrix comprises collagen, elastin, and vascularchannels. In some embodiments, the acellular tissue matrix is ALLODERM®.In some embodiments, the acellular tissue matrix is STRATTICE™.

In some embodiments, a method for producing a tissue scaffold isprovided In some embodiments, a method comprises adding an acellulartissue matrix to a first aqueous solution of sodium acetate; incubatingthe first aqueous sodium acetate solution containing the acellulartissue matrix; removing the incubated acellular tissue matrix from thefirst aqueous sodium acetate solution; treating the incubated acellulartissue matrix with a second aqueous solution of sodium acetate to form asuspension; homogenizing the suspension to form a slurry; cooling theslurry; casting the slurry in a casting container; and lyophilizing thefrozen slurry.

In some embodiments, the acellular tissue matrix added to the firstaqueous sodium acetate solution is in dehydrated form. In someembodiments, the acellular tissue matrix is cut into small pieces, e.g.,cubes, after removal from the first aqueous sodium acetate solutionprior to homogenization. In some embodiments, the incubating step takesplace at about 4° C. for more than 12 hours.

In some embodiments, the homogenizing step and the cooling step arerepeated at least three times. In some embodiments, the homogenizingstep is accomplished by a homogenizing Dremmel probe. In someembodiments, the cooling step is accomplished at about 0° C. for about1.5 minutes or longer. In some embodiments, the casted slurry is frozenat about −70° C. or less for about 2 hours or longer. In someembodiments, the casted slurry is frozen at about −200° C. or less.

In some embodiments, the desired shape and height of the resultingtissue scaffold is determined by the shape and height of the castingcontainer. In some embodiments, the first aqueous sodium acetatesolution has a pH of about 3.4, or between about 3.4 and 7.0, or betweenabout 3.4 and 5.0. In some embodiments, the first aqueous solutionachieves a final concentration of about 0.1% w/v to about 15% w/v ofacellular tissue matrix. In some embodiments, the porosity of theresulting tissue scaffold is from about 75% to about 90%. In someembodiments, the strut density of the resulting tissue scaffold is fromabout 0.13 g/cm³ to about 0.24 g/cm³. In some embodiments, mechanicalstrength, porosity, hydration and fluid conductance are controlled byfreezing rate, freezing temperature, and the composition of the castingcontainer. In some embodiments, the acellular tissue matrix comprisescollagen, elastin, and vascular channels. In some embodiments, theacellular tissue matrix is ALLODERM®. In some embodiments, the acellulartissue matrix comprises collagen, elastin, and vascular channels. Insome embodiments, the acellular tissue matrix is STRATTICE™.

In certain embodiments, the tissue scaffold has a desired permeability.For example, the permeability may be selected to allow adequatemanifolding or distribution of pressure or flow applied to a wound ortherapy site across the site. In certain embodiments, the permeabilityis controlled by controlling the porosity of the tissue scaffold. Incertain embodiments, the permeability is at least 1×10¹¹ m².

In some embodiments, sodium bicarbonate is further added to either oneor both of the first or second aqueous sodium acetate solutions, and/orto the slurry. In some embodiments, sodium bicarbonate can be added tothe solution just before or during casting. The amount of sodium acetatecan be selected to cause foaming of the solution and/or slurry. Incertain embodiments, the amount of foaming is selected to control theporosity of all or a portion of a tissue scaffold. In certainembodiments, the slurry is frozen soon after adding sodium acetate tocreate a desired porosity in the tissue scaffold. In some embodiments,the tissue scaffold can have a porosity that varies across itsthickness.

In some embodiments, the tissue scaffold comprises an acellular tissuematrix and sodium acetate. In some embodiments, the tissue scaffoldfurther comprises sodium bicarbonate.

In certain instances, it may be desirable for tissue scaffolds to beresorbed by the body rather than persist for extended periods. Incertain instances, tissue scaffolds persist for extended periods, e.g.,several months or longer. In certain instances, extended periods providecontinued tissue regrowth, remodeling, and regeneration. In certaininstances, with some negative pressure wound treatment systems, amaterial placed over a wound bed is generally replaced periodically(e.g., every few days). In certain instances, replacement of thematerials can be painful or damaging to the wound site, especially ifgranulation tissue has grown into the material. In some embodiments, thetissue scaffolds are bioresorbable. In some embodiments, the tissuescaffolds can be placed in a wound site or implanted, and will beresorbed by the body such that the devices are not removed or replaced.

The following examples demonstrate certain exemplary embodiments of thedisclosure. It should be appreciated by those of skill in the art thatthe techniques disclosed in the examples herein may be modified toachieve similar results.

Preparation of a Tissue Scaffold

Aseptically prepared ALLODERM® is cut into strips (approximately 2-3 mmwide) and weighed dry. The desired weight is immersed in the appropriatevolume of 20 mM sodium acetate to achieve a final concentration of about0.1% to about 15.0% w/v (weight of dried material to volume ofsolution). The strips are then removed from solution, diced into smallcubes (approximately 2×2 mm) using a scalpel, and immersed in a second20 mM aqueous sodium acetate solution to achieve the desired % w/v. Thesuspension is then homogenized at full speed using a Dremmel type probetip for 1 minute, followed by cooling on ice for about 1 minute orlonger. The suspension is cooled sufficiently to prevent heating of thesuspension to near the melting point of collagen within the suspensionduring subsequent homongenization, thereby preventing thermal damage tothe collagen. The homogenization and cooling steps are repeated three(3) times. The homogenizer tip is then rinsed, and the slurry is thenpoured into the desired casting containers for the right shape andheight. The containers are then covered and placed in a freezer at −70°C. for more than 2 hours to ensure complete freezing. As describedbelow, samples may be frozen at other temperatures to achieve fasterfreezing, e.g., on liquid nitrogen at about −200° C. The samples areremoved from the freezer and placed in a freeze drier. The scaffolds arethen removed from the freeze drier upon completion (e.g., about 24 hoursor when the temperature of the vessel reaches ambient temperature) ofthe lyophilization process, and are stored in a dessicator or undervacuum. In some embodiments, sodium bicarbonate can be added to thesample before or after any of the homogenization steps, or just beforeor during casting.

In various embodiments, freezing rate, freezing temperature, theaddition of sodium bicarbonate and the material compositions may all bemodified. In certain embodiments, the modifications control the finalcomposition, mechanical strength, hydration, and/or fluid conductance ofthe resulting tissue scaffold.

Example 1: Effect of Scaffold Thickness on Strut Spacing

The effect of material thickness on scaffold structure was evaluated.Aseptically prepared ALLODERM® was cut into strips (approximately 2-3 mmwide) and weighed dry. The strips were immersed in the appropriatevolume of 20 mM sodium acetate to achieve a final concentration of 5.0%w/v (weight of dried material to volume of solution) and pH of about3.4. The samples were incubated overnight at 4° C. After incubationovernight, the sample pH rose to about 7.0, and the pH was adjusted backto about 3.4 before further processing. Samples were homogenized threetimes using a Dremmel type probe to produce a slurry. Samples werecooled on ice for 1 minute between each homogenization step. The sampleswere casted in six-well culture plates. The wells in which samples werecasted had a cylindrical structure with a 35 mm diameter. Samples werecooled at −70° C. for four hours and were then freeze-dried to producetissue scaffolds. Scaffolds were produced using slurry volumes of 1 ml,2 ml, 4 ml, and 6 ml. FIGS. 3A-3D are graphs showing the strut spacingfor the tissue scaffolds. FIG. 3A represents data for a 1 ml sample,FIG. 3B is date for a 2 ml sample, FIG. 3C is data for a 4 ml sample,and FIG. 3D is data for a 6 ml sample.

As shown in FIGS. 3A-3D, thicker samples resulted in a larger pore size(larger strut spacing) and wider variation pore size. Table 1 providesdata including the average pore size, standard deviation, median poresize, and minimum and maximum pore sizes for samples having varyingthicknesses. As shown in Table 1, the standard deviation of pore size,range of pore sizes (difference between minimum and maximum pore sizes)and average pore size all increase with increasing material thickness.

TABLE 1 Final Volume of NaOAc for Scaffolds Produced with 5% w/v Slurry(material to casting solution) 1 ml 2 ml 4 ml 6 ml Average Strut 89 μm108 μm 133 μm 212 μm Spacing Standard 29 μm 41 μm 51 μm 67 μm Deviationof Strut Spacing Median Strut 83 μm 101 μm 97 μm 202 μm Spacing MaximumStrut 167 μm 211 μm 260 μm 356 μm Spacing Minimum Strut 43 μm 33 μm 35μm 96 μm Spacing

Example 2: Effect of Scaffold Composition on Water-Binding Capacity,Porosity, and Permeability

In certain embodiments, the ability of tissue scaffolds to bind watercan be important for scaffolds remaining hydrated and being effective insupporting tissue repair or regeneration. Sample permeability andwater-binding capacity were studied as a function of sample composition(i.e., variation in w/v %). Scaffolds were produced by casting andlyophilizing slurries having varying compositions.

Aseptically prepared ALLODERM® was cut into strips (approximately 2-3 mmwide) and weighed dry. The desired weight of the strips was immersed inthe appropriate volume of 20 mM sodium acetate to achieve a finalconcentrations of 0.1% w/v, 0.5% w/v, 1.0% w/v, 3.0% w/v, 5% w/v, and 8%w/v (each being material weight to sodium acetate solution volume). Eachsample pH was about 3.4. Samples were incubated overnight at 4° C. Afterincubation, the sample pHs rose to about 7.0, and the pHs were adjustedback to about 3.4 before further processing. Samples were homogenizedthree times using a Dremmel type probe to produce a slurry. Samples werecooled on ice for 1 minute between each homogenization step. Sampleswere cooled at −70° C. for four hours and were then freeze-dried toproduce tissue scaffolds.

Table 2 provides data for sample water-binding capacity as a function ofsample composition, and FIG. 4 is a graph showing the permeabilityversus composition for tissue scaffolds. As shown in Table 2 and FIG. 4,as the sample w/v % increased, the sample water-binding capacityincreased and sample permeability decreased.

TABLE 2 Soaking Capacity of Exemplary Tissue Scaffolds Dry AlloDerm/Soaking Thickness Length Breadth Volume NaOac Capcity (% (% (% (% (w/v)(g/cm³) change) change) change) change) 0.1% n/a −79.2 8.5 5.6 −76.10.5% 0.53 −42.9 1.5 1.6 −41.0 1.0% 0.32 3.8 2.3 3.4 9.8 3.0% 0.56 3.62.4 2.6 8.8 5.0% 0.68 7.6 6.7 4.8 20.3 8.0% 0.80 9.1 0.7 0.8 10.8

Table 3 provides data on sample strut density and porosity as a functionof sample composition. The sample porosity followed a relatively normaldistribution, with sample strut spacing and porosity increasing assample composition varies from 0.1% to about 5.0%, and decreasing withfurther increase in sample composition.

TABLE 3 Porosity and Strut Density of Tissue Scaffolds DryAlloDerm/NaOAc (w/v) Strut Density (g/cm³) % Porosity 0.1% 0.132 89.00.5% 0.075 84.6 1.0% 0.154 89.9 4.0% 0.264 88.7 5.0% 0.423 91.0 8.0%0.486 89.2 10.0% 0.395 84.1 15.0% 0.234 79.7

Example 3: Effect of Freezing Rate/Temperature on Scaffold Structure

TABLE 4 Foam Strut Spacing for Samples Cooled at −200° C. Foam StrutSpacing (microns) Average 9.5 Standard Deviation 2.2 Median 9.7 Maximum14.2 Minimum 4.2

Example 4: Culture of Isolated Chondrocytes on Tissue Scaffolds

FIGS. 6A-6B are photomicrographs of chondrocytes cultured on tissuescaffolds produced with ALLODERM®, and FIGS. 7A-7B are photomicrographsof chondrocytes cultured on tissue scaffolds produced with STRATTICE™.Both human and porcine tissue scaffolds supported chondrocyte growth andinfiltration, and grossly appeared to maintain chondrocyte phenotypes.

While systems and methods have been described with reference to tissuegrowth and healing in human patients, it should be recognized that thesesystems and methods for applying reduced pressure tissue treatment canbe used in any living organism in which it is desired to promote tissuegrowth or healing. Similarly, the systems and methods may be applied toany tissue, including without limitation bone tissue, adipose tissue,muscle tissue, neural tissue, dermal tissue, vascular tissue, connectivetissue, cartilage, tendons, or ligaments. While the healing of softtissue may be an exemplary focus of applying reduced pressure tissuetreatment as described herein, the application of reduced pressuretissue treatment, especially to tissues located beneath a patient'sskin, may also be used to generate tissue growth in tissues that are notdiseased, defective, or damaged. For example, it may be desired to usethe percutaneous implantation techniques to apply reduced pressuretissue treatment to grow additional tissue at a tissue site that canthen be harvested. The harvested tissue may be transplanted to anothertissue site to replace diseased or damaged tissue, or alternatively theharvested tissue may be transplanted to another patient.

Other embodiments will be apparent to those skilled in the art fromconsideration of the specification and practice of the devices andmethods disclosed herein.

What is claimed is:
 1. A wound treatment device comprising: a reducedpressure source; a flexible sheet configured to cover a wound site; atissue scaffold comprising a porous acellular tissue matrix foam; and amanifold applied over the tissue scaffold to distribute pressure to thetissue scaffold.
 2. The wound treatment device of claim 1, wherein thereduced pressure source includes a pump.
 3. The wound treatment deviceof claim 1, wherein the acellular tissue matrix comprises collagen,elastin, and vascular channels.
 4. The wound treatment device of claim1, wherein the acellular tissue matrix is a dermal acellular tissuematrix.
 5. The wound treatment device of claim 4, wherein the acellulartissue matrix is a human dermal acellular tissue matrix.
 6. The woundtreatment device of claim 4, wherein the acellular tissue matrix is aporcine dermal acellular tissue matrix.
 7. The wound treatment device ofclaim 1, wherein the porosity of the tissue scaffold is from 75% to 90%.8. The wound treatment device of claim 1, wherein the tissue scaffoldhas a permeability of at least 1×10⁻¹¹ m² or greater.
 9. The woundtreatment device of claim 1, wherein the strut density of the tissuescaffold is from about 0.13 g/cm³ to about 0.24 g/cm³.
 10. The woundtreatment device of claim 1, wherein the tissue scaffold has awater-binding capacity of at least 0.5 g/cm³.
 11. The wound treatmentdevice of claim 1, wherein the flexible sheet comprises a flexiblepolymeric material.
 12. The wound treatment device claim 1, furthercomprising an adhesive comprising a cement, glue, or resin.
 13. Thewound treatment device of claim 12, wherein the adhesive comprises apressure-sensitive acrylic adhesive.
 14. The wound treatment deviceaccording to claim 12, wherein the adhesive can be applied to a surfaceof the flexible sheet to attach the flexible sheet to skin or othertissue.
 15. The wound treatment device of claim 1, wherein the porousacellular tissue matrix foam is produced by: adding an acellular tissuematrix to a first aqueous solution; incubating the first aqueoussolution containing the acellular tissue matrix; removing the incubatedacellular tissue matrix from the first aqueous solution; treating theincubated acellular tissue matrix with a second aqueous solution to forma suspension; homogenizing the suspension to form a slurry; cooling theslurry; casting the slurry in a casting container; and lyophilizing theslurry.
 16. The wound treatment device of claim 15, wherein thehomogenizing and cooling are repeated at least three times.
 17. Thewound treatment device of claim 1, wherein the first aqueous sodiumacetate solution has a pH between about 3.4 and 7.0.
 18. The woundtreatment device of claim 1, further comprising a fluid conduitconnecting the reduced pressure source to the wound site.
 19. The woundtreatment device of claim 1, wherein the flexible sheet at leastpartially seals the wound to allow reduced pressure therapy to beprovided at the wound site.
 20. The wound treatment device of claim 1,wherein the tissue scaffold facilitates wound closure, healing, tissueregeneration or repair, and prevents or treats infection.
 21. The woundtreatment device of claim 1, wherein the foam comprises homogenizedacellular tissue matrix particles.
 22. The wound treatment device ofclaim 1, wherein the foam comprises lyophilized acellular tissue matrix23. The wound treatment device of claim 22, wherein the acellular tissuematrix comprises particulate tissue matrix.